glp-1 lawsuit news today 2025 Societies take stand against off-brand GLP-1s over safety concerns The New York Times spotlighted

While US studies have highlighted vast eligibility [4] and noted low but increasing initiation rates of anti-obesity medications (1.8%) with significant access disparities [5, 6], the situation in healthcare systems with substantial out-of-pocket costs warrants specific examination

It is a measurement for oxidative stress and can help detect diseases in the liver or bile ducts

It tends to happen more gradually over time, to the point where you may not notice the changes right away or that they are even significant, explains Garshick

Full-text articles were retrieved for studies deemed potentially eligible, and discrepancies were resolved by discussion or consensus with a third reviewer